Finance

Lists
AARD:NASDAQ
Aardvark Therapeutics Inc
5,35 $
0,00%
(0,00) 1D
5,25 $
-1,87% (-0,100)
Pre-market
Closed: 29 սեպ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AARD...
Mkt. cap
117,08 մլն
Avg. vol.
129,08 հզր
Volume
12,00 հզր
52-wk high
17,94 $
52-wk low
3,35 $
EPS
-3,21 $
Shares outstanding
21,88 մլն
No. of employees
28
Mkt. cap
117,08 մլն
Avg. vol.
129,08 հզր
Volume
12,00 հզր
52-wk high
17,94 $
52-wk low
3,35 $
EPS
-3,21 $
Shares outstanding
21,88 մլն
No. of employees
28
News stories
From web sources and news partners
About Aardvark Therapeutics Inc
CEO-
Employees28
Founded2017
Headquarters-
Sector-
Websiteaardvarktherapeutics.com
Analyst ratings
Based on 7 analysts giving stock ratings to AARD in the past 3 months
Hold
Buy
1
Hold
4
Sell
2
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for AARD in the last 3 months.
Highest
Current 5,35 $
6,00 $ (+12,15%)
Average
5,25 $ (-1,87%)
Lowest
3,00 $ (-43,93%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brian Abrahams
RBC Capital
Hold
Maintained
6,00 $
+12,1%
09/24/2026
Tazeen Ahmad
Bank of America Securities
Sell
Maintained
-
-
08/14/2026
James Condulis
Stifel Nicolaus
Hold
Reiterated
6,00 $
+12,1%
08/13/2026
Jeet Mukherjee
BTIG
Hold
Maintained
-
-
08/12/2026
Michael Ulz
Morgan Stanley
Sell
Reiterated
3,00 $
-43,9%
08/12/2026
Andy Hsieh
William Blair
Buy
Reiterated
-
-
08/12/2026
Ram Selvaraju
H.C. Wainwright
Hold
Reiterated
6,00 $
+12,1%
07/20/2026
William Wood
B. Riley Securities
Buy
Maintained
7,00 $
+30,8%
05/15/2026
Tim Anderson
Bank of America Securities
Buy
Reiterated
18,00 $
+236,4%
05/08/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Maintained
45,00 $
+741,1%
03/02/2026
Leland Gershell
Oppenheimer
Buy
Maintained
21,00 $
+292,5%
02/27/2026
Last report
11 օգս, 2026 թ.
Fiscal period
Q2 2026
EPS / Est. (USD)
-0,66 $ / -0,88 $
+25,11%beat
Revenue / Est. (USD)
- / 0,00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
13,74 մլն
14,30 մլն
16,57 մլն
10,46 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,97 մլն
4,40 մլն
5,90 մլն
4,63 մլն
Operating expense
17,70 մլն
18,70 մլն
22,46 մլն
15,08 մլն
Total operating expenses
17,70 մլն
18,70 մլն
22,46 մլն
15,08 մլն
Operating income
-17,70 մլն
-18,70 մլն
-22,46 մլն
-15,08 մլն
Other non operating income
-
-
-
-
EBT including unusual items
-16,32 մլն
-17,60 մլն
-21,59 մլն
-14,39 մլն
EBT excluding unusual items
-16,35 մլն
-17,58 մլն
-21,58 մլն
-14,39 մլն
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-16,32 մլն
-17,60 մլն
-21,59 մլն
-14,39 մլն
Net profit margin
-
-
-
-
Earnings per share
-0,75
-0,81
-0,99
-0,66
Interest and investment income
1,35 մլն
1,12 մլն
889,00 հզր
695,00 հզր
Interest expense
-
-
-
-
Net interest expenses
1,35 մլն
1,12 մլն
889,00 հզր
695,00 հզր
Depreciation and amortization charges
-
-
-
-
EBITDA
-17,69 մլն
-18,69 մլն
-22,45 մլն
-15,07 մլն
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google Apps